Could an HIV drug extend life in Creutzfeldt-Jakob disease?
NCT ID NCT07482085
First seen Mar 26, 2026 · Last updated Jun 20, 2026 · Updated 19 times
Summary
This study tests whether efavirenz, a drug used for HIV, can help people with Creutzfeldt-Jakob disease (CJD) live longer. CJD is a rare, rapidly fatal brain disorder. The trial will enroll 246 adults and randomly assign them to receive either efavirenz or a placebo. The main goal is to see if efavirenz extends survival time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CREUTZFELDT-JAKOB DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Capital Medical University
Beijing, 100053, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Efavirenz (an anti-HIV drug)
What this could lead to
If it works, this could point toward a treatment that extends survival and slows decline in people with Creutzfeldt-Jakob disease.
What could go wrong
This is an early Phase 3 trial, and efavirenz has not been proven effective for CJD before. The disease is rapidly fatal, and the drug may cause side effects or fail to show benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.